Drug Development and Potential Regulatory Paths for Insulin Biosimilars

Area of Science:

• Biopharmaceutical science
• Regulatory science
• Endocrinology

Background:

• The Biologics Price Competition and Innovation Act (BPCI Act) defines biosimilarity based on high similarity to reference products.
• Biosimilar insulins offer a potential solution to escalating insulin treatment costs by fostering market competition.
• Existing regulatory frameworks provide general guidance but lack specific product guidance for insulin biosimilars.

Purpose of the Study:

• To describe current drug development and regulatory pathways for biosimilar insulins.
• To discuss the likely basis for market approval by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) guidance.
• To propose efficient, cost-effective development and regulatory strategies, including novel trial designs for interchangeability.

Main Methods:

• Review of existing regulatory guidelines from the FDA and EMA.
• Analysis of the BPCI Act requirements for biosimilarity.
• Proposal of scientific justification-based development and regulatory pathways.
• Presentation of novel clinical trial designs for demonstrating interchangeability.

Main Results:

• Currently, no specific FDA guidance exists for insulin biosimilarity assessment.
• Efficient and cost-effective development and regulatory paths are proposed.
• Novel trial designs for assessing interchangeability are presented.

Conclusions:

• Biosimilar insulins have significant potential to reduce healthcare costs.
• Streamlined and scientifically justified regulatory pathways are crucial for timely market entry.
• Demonstrating interchangeability through innovative trial designs is key for patient access and therapeutic substitution.